173 related articles for article (PubMed ID: 24820076)
1. Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6.
Court MH; Almutairi FE; Greenblatt DJ; Hazarika S; Sheng H; Klein K; Zanger UM; Bourgea J; Patten CJ; Kwara A
Antimicrob Agents Chemother; 2014 Jul; 58(7):4145-52. PubMed ID: 24820076
[TBL] [Abstract][Full Text] [Related]
2. Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.
Bertrand J; Verstuyft C; Chou M; Borand L; Chea P; Nay KH; Blanc FX; Mentré F; Taburet AM;
J Infect Dis; 2014 Feb; 209(3):399-408. PubMed ID: 23990572
[TBL] [Abstract][Full Text] [Related]
3. Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.
McIlleron HM; Schomaker M; Ren Y; Sinxadi P; Nuttall JJ; Gous H; Moultrie H; Eley B; Merry C; Smith P; Haas DW; Maartens G
AIDS; 2013 Jul; 27(12):1933-40. PubMed ID: 24180002
[TBL] [Abstract][Full Text] [Related]
4. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation.
Ogburn ET; Jones DR; Masters AR; Xu C; Guo Y; Desta Z
Drug Metab Dispos; 2010 Jul; 38(7):1218-29. PubMed ID: 20335270
[TBL] [Abstract][Full Text] [Related]
5. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Manosuthi W; Sukasem C; Lueangniyomkul A; Mankatitham W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
Antimicrob Agents Chemother; 2013 Feb; 57(2):1019-24. PubMed ID: 23254426
[TBL] [Abstract][Full Text] [Related]
6. CYP2B6 Genotype-Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers.
Metzger IF; Dave N; Kreutz Y; Lu JBL; Galinsky RE; Desta Z
Clin Transl Sci; 2019 Nov; 12(6):657-666. PubMed ID: 31339646
[TBL] [Abstract][Full Text] [Related]
7. Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
Xu C; Ogburn ET; Guo Y; Desta Z
Drug Metab Dispos; 2012 Apr; 40(4):717-25. PubMed ID: 22232427
[TBL] [Abstract][Full Text] [Related]
8. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.
Haas DW; Kwara A; Richardson DM; Baker P; Papageorgiou I; Acosta EP; Morse GD; Court MH
J Antimicrob Chemother; 2014 Aug; 69(8):2175-82. PubMed ID: 24729586
[TBL] [Abstract][Full Text] [Related]
9. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.
Kwara A; Lartey M; Sagoe KW; Kenu E; Court MH
AIDS; 2009 Oct; 23(16):2101-6. PubMed ID: 19779319
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping.
Gausi K; Wiesner L; Norman J; Wallis CL; Onyango-Makumbi C; Chipato T; Haas DW; Browning R; Chakhtoura N; Montepiedra G; Aaron L; McCarthy K; Bradford S; Vhembo T; Stranix-Chibanda L; Masheto GR; Violari A; Mmbaga BT; Aurpibul L; Bhosale R; Nevrekhar N; Rouzier V; Kabugho E; Mutambanengwe M; Chanaiwa V; Nyati M; Mhembere T; Tongprasert F; Hesseling A; Shin K; Zimmer B; Costello D; Jean-Philippe P; Sterling TR; Theron G; Weinberg A; Gupta A; Denti P;
Clin Pharmacol Ther; 2021 Apr; 109(4):1034-1044. PubMed ID: 32909316
[TBL] [Abstract][Full Text] [Related]
11. Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.
Luetkemeyer AF; Rosenkranz SL; Lu D; Grinsztejn B; Sanchez J; Ssemmanda M; Sanne I; McIlleron H; Havlir DV; Haas DW;
Clin Infect Dis; 2015 Jun; 60(12):1860-3. PubMed ID: 25722197
[TBL] [Abstract][Full Text] [Related]
12. Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers.
Cho DY; Shen JH; Lemler SM; Skaar TC; Li L; Blievernicht J; Zanger UM; Kim KB; Shin JG; Flockhart DA; Desta Z
Drug Metab Pharmacokinet; 2016 Apr; 31(2):107-16. PubMed ID: 27053325
[TBL] [Abstract][Full Text] [Related]
13. CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
Kwara A; Lartey M; Sagoe KW; Rzek NL; Court MH
Br J Clin Pharmacol; 2009 Apr; 67(4):427-36. PubMed ID: 19371316
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis.
Agyemang N; Scarsi KK; Baker P; Smeaton LM; Podany AT; Olefsky M; Woolley E; Barr E; Pham M; Mawlana S; Supparatpinyo K; Gatechompol S; Jalil EM; Gadama L; Badal-Faesen S; Van Schalkwyk M; Kayama C; Belaunzaran-Zamudio PF; Godfrey C; Cohn SE; Mngqibisa R; Haas DW;
Pharmacogenet Genomics; 2023 Aug; 33(6):126-135. PubMed ID: 37306344
[TBL] [Abstract][Full Text] [Related]
15. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
Wen X; Wang JS; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS).
van Rensburg R; Nightingale S; Brey N; Albertyn CH; Kellermann TA; Taljaard JJ; Esterhuizen TM; Sinxadi PZ; Decloedt EH
Clin Infect Dis; 2022 Aug; 75(3):399-405. PubMed ID: 34882770
[TBL] [Abstract][Full Text] [Related]
17. CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.
Dhoro M; Zvada S; Ngara B; Nhachi C; Kadzirange G; Chonzi P; Masimirembwa C
BMC Pharmacol Toxicol; 2015 Mar; 16():4. PubMed ID: 25889207
[TBL] [Abstract][Full Text] [Related]
18. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.
Ward BA; Gorski JC; Jones DR; Hall SD; Flockhart DA; Desta Z
J Pharmacol Exp Ther; 2003 Jul; 306(1):287-300. PubMed ID: 12676886
[TBL] [Abstract][Full Text] [Related]
19. Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old.
Kwara A; Yang H; Antwi S; Enimil A; Gillani FS; Dompreh A; Ortsin A; Opoku T; Bosomtwe D; Sarfo A; Wiesner L; Norman J; Alghamdi WA; Langaee T; Peloquin CA; Court MH; Greenblatt DJ
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397066
[TBL] [Abstract][Full Text] [Related]
20. CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling.
Xu C; Quinney SK; Guo Y; Hall SD; Li L; Desta Z
Drug Metab Dispos; 2013 Dec; 41(12):2004-11. PubMed ID: 23846872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
